A Mouse/human Chimeric Anti-(ganglioside GD3) Antibody with Enhanced Antitumor Activities

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 1993 Jun 1

PMID 8500110

Citations 3

Authors

K Shitara

Y Kuwana

K Nakamura

Y Tokutake

S Ohta

H Miyaji

M Hasegawa

N Hanai

Affiliations

Soon will be listed here.

Abstract

Ganglioside GD3, which is one of the major gangliosides expressed on the cell surface of human tumors of neuroectodermal origin has been focused on as a target molecule for passive immunotherapy. We have cloned the cDNA encoding the immunoglobulin light and heavy chains of an anti-GD3 monoclonal antibody KM641 (murine IgG3, kappa), and constructed the chimeric genes by linking the cDNA fragments of the murine light and heavy variable regions to cDNA fragments of the human kappa and gamma 1 constant regions, respectively. The transfer of these cDNA constructs into SP2/0 mouse myeloma cells resulted in the production of the chimeric antibody, designated KM871, that retained specific binding activity to GD3. Indirect immunofluorescence revealed the same staining pattern for chimeric KM871 and the mouse counterpart KM641 on GD3-expressing melanoma cells. When human serum and human peripheral blood mononuclear cells were used as effectors in complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity respectively, the chimeric KM871 was more effective in killing GD3-expressing tumor cells than was the mouse counterpart KM641. Intravenous injection of chimeric KM871 markedly suppressed tumor growth in nude mice. The chimeric KM871, having enhanced antitumor activities and less immunogenicity than the mouse counterpart, would be a useful agent for passive immunotherapy of human cancer.

Citing Articles

Application of the Antibody-Inducing Activity of Glycosphingolipids to Human Diseases.

Okuda T Int J Mol Sci. 2021; 22(7).

PMID: 33917390 PMC: 8038663. DOI: 10.3390/ijms22073776.

Generation and Improvement of Effector Function of a Novel Broadly Reactive and Protective Monoclonal Antibody against Pneumococcal Surface Protein A of Streptococcus pneumoniae.

Kristian S, Ota T, Bubeck S, Cho R, Groff B, Kubota T PLoS One. 2016; 11(5):e0154616.

PMID: 27171010 PMC: 4865217. DOI: 10.1371/journal.pone.0154616.

Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer.

Nishihara T, Sawada T, Yamamoto A, Yamashita Y, Ho J, Kim Y Jpn J Cancer Res. 2000; 91(8):817-24.

PMID: 10965023 PMC: 5926427. DOI: 10.1111/j.1349-7006.2000.tb01019.x.

References

Hanai N, Furuya A, Shitara K, Oda S, Yoshida H . Comparative studies on monoclonal antibodies raised against human gastric cancer for application to serum diagnosis of cancer. Anticancer Res. 1988; 8(3):329-34. View

Tsuchida T, Saxton R, Morton D, Irie R . Gangliosides of human melanoma. J Natl Cancer Inst. 1987; 78(1):45-54. DOI: 10.1093/jnci/78.1.45. View

Rinfret A, Horne C, Boux H, Marks A, DORRINGTON K, Klein M . Isotype modulation of idiotypic expression in recombinant isotypic variants of MOPC 315. J Immunol. 1990; 145(3):925-31. View

Miyaji H, Harada N, Mizukami T, Sato S, Fujiyoshi N, Itoh S . Efficient expression of human beta-interferon in Namalwa KJM-1 cells adapted to serum-free medium by a dhfr gene coamplification method. Cytotechnology. 1990; 4(2):173-80. DOI: 10.1007/BF00365098. View

Cheung N, Lazarus H, MIRALDI F, Abramowsky C, Kallick S, Saarinen U . Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987; 5(9):1430-40. DOI: 10.1200/JCO.1987.5.9.1430. View

Irie R, Morton D . Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci U S A. 1986; 83(22):8694-8. PMC: 386997. DOI: 10.1073/pnas.83.22.8694. View

Liu A, Robinson R, Hellstrom K, Murray Jr E, Chang C, Hellstrom I . Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A. 1987; 84(10):3439-43. PMC: 304886. DOI: 10.1073/pnas.84.10.3439. View

Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C . Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol. 1988; 6(10):1636-48. DOI: 10.1200/JCO.1988.6.10.1636. View

Winter G, Milstein C . Man-made antibodies. Nature. 1991; 349(6307):293-9. DOI: 10.1038/349293a0. View

10.

Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S . Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987; 149(3):960-8. DOI: 10.1016/0006-291x(87)90502-x. View

11.

Hieter P, Max E, Seidman J, Maizel Jr J, Leder P . Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments. Cell. 1980; 22(1 Pt 1):197-207. DOI: 10.1016/0092-8674(80)90168-3. View

12.

Miyaji H, Mizukami T, Hosoi S, Sato S, Fujiyoshi N, Itoh S . Expression of human beta-interferon in Namalwa KJM-1 which was adapted to serum-free medium. Cytotechnology. 1990; 3(2):133-40. DOI: 10.1007/BF00143675. View

13.

Kameyama K, Imai K, Itoh T, Taniguchi M, Miura K, Kurosawa Y . Convenient plasmid vectors for construction of chimeric mouse/human antibodies. FEBS Lett. 1989; 244(2):301-6. DOI: 10.1016/0014-5793(89)80550-2. View

14.

Hanai N, Shitara K, Furuya A, Yoshida H, Dohi T, Nudelman E . Detailed characterization of reactivities of anti-gastric cancer monoclonal antibodies to carbohydrate antigen. Anticancer Res. 1990; 10(6):1579-86. View

15.

Cheresh D, Harper J, Schulz G, Reisfeld R . Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci U S A. 1984; 81(18):5767-71. PMC: 391792. DOI: 10.1073/pnas.81.18.5767. View

16.

Real F, Houghton A, Albino A, Cordon-Cardo C, Melamed M, Oettgen H . Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res. 1985; 45(9):4401-11. View

17.

Khazaeli M, Saleh M, Wheeler R, Huster W, HOLDEN H, Carrano R . Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst. 1988; 80(12):937-42. DOI: 10.1093/jnci/80.12.937. View

18.

Dippold W, LLOYD K, Li L, Ikeda H, Oettgen H, Old L . Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1980; 77(10):6114-8. PMC: 350224. DOI: 10.1073/pnas.77.10.6114. View

19.

Bernhard H, Roth S, Bauerschmitz J, Meyer zum Buschenfelde K, Dippold W . Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues. Int J Cancer. 1992; 51(4):568-72. DOI: 10.1002/ijc.2910510411. View

20.

Houghton A, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S . Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A. 1985; 82(4):1242-6. PMC: 397231. DOI: 10.1073/pnas.82.4.1242. View